Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston oilfield completions and drilling (NYSE: HAL) $22.9B FY2024 revenue; #1 US hydraulic fracturing, Zeus E-frac, international expansion, $4.0B adj. operating income competing with SLB and Baker Hughes.
Halliburton Company is a Houston, Texas-based oilfield services company — publicly traded on the New York Stock Exchange (NYSE: HAL) as an S&P 500 Energy component — providing products and services for the exploration, development, and production of oil and natural gas through two segments: Completion and Production (hydraulic fracturing, cementing, artificial lift, wireline logging) and Drilling and Evaluation (drill bits, directional drilling, formation evaluation, well construction planning) through approximately 50,000 employees in 70+ countries. In fiscal year 2024, Halliburton reported revenues of $22.9 billion and adjusted operating income of $4.0 billion, with North America (the most important market — driven by US shale completions) generating $8.6 billion and international operations (Middle East, Latin America, Africa, Europe) generating $14.3 billion. CEO Jeff Miller has led Halliburton's return to strong profitability following the COVID-19 oil demand collapse with a disciplined capital-light model: rather than owning all completion equipment (pressure pumping fleets, cementing units), Halliburton has entered long-term customer partnerships where major E&P operators (Pioneer, EOG, Devon, ConocoPhillips) commit multi-year completion work to Halliburton in exchange for deployment priority and dedicated crew relationships — reducing equipment idle time and Halliburton's capital requirements while securing predictable activity levels. Halliburton's Zeus electric fracturing fleet (E-frac using natural gas-powered electric motors to drive frac pumps rather than diesel engines) reduces NOx emissions and fuel cost for US shale operators — achieving 40-50% fuel cost reduction that operators increasingly specify as a sustainability requirement.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.